From: XRCC1 and XPDgenetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study
<5 pack-years | >5 pack-years | |||||
---|---|---|---|---|---|---|
Cases n (%) | Controls n (%) | OR (95% CI)a | Cases n (%) | Controls n (%) | OR (95% CI)a | |
XRCC1-280 | ||||||
Arg/Arg | 37 (82.2) | 51 (82.3) | 1.0 | 57 (85.1) | 60 (89.6) | 1.0 |
Arg/His+His/His | 8 (17.8) | 11 (17.7) | 0.91 (0.28–2.95) | 10 (14.9) | 7 (10.4) | 1.99 (0.57–7.02) |
XRCC1-399 | ||||||
Arg/Arg | 20 (44.4) | 35 (57.4) | 1.0 | 25 (37.9) | 40 (59.7) | 1.0 |
Arg/Gln | 18 (40.0) | 22 (36.1) | 1.21 (0.46–3.18) | 31 (47.0) | 21 (31.3) | 4.31 (1.66–11.2) |
Gln/Gln | 7 (15.6) | 4 (6.6) | 3.99 (0.82–19.4) | 10 (15.2) | 6 (9.0) | 3.55 (0.81–15.6) |
Arg/Gln+Gln/Gln | 25 (55.6) | 26 (42.6) | 1.61 (0.64–4.06) | 41 (62.1) | 27 (40.3) | 4.14 (1.66–10.3) |
XPD-751 | ||||||
Lys/Lys | 18 (40.0) | 20 (32.3) | 1.0 | 22 (32.8) | 20 (29.9) | 1.0 |
Lys/Gln | 18 (40.0) | 31 (50.0) | 1.01 (0.37–2.77) | 22 (32.8) | 38 (56.7) | 0.40 (0.14–1.12) |
Gln/Gln | 9 (20.0) | 11 (17.7) | 1.59 (0.44–5.74) | 23 (34.3) | 9 (13.4) | 2.77 (0.90–8.59) |
Lys/Lys+Lys/Gln | 36 (80.0) | 51 (82.3) | 1.0 | 44 (65.7) | 58 (86.6) | 1.0 |
Gln/Gln | 9 (20.0) | 11 (17.7) | 1.45 (0.46–4.56) | 23 (34.3) | 9 (13.4) | 4.41 (1.62–12.0) |